Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANIX Anixa Biosciences	$2.66 +1.9%	$2.78	$2.07 ▼ $4.20	$85.64M	0.43	90,687 shs	74,195 shs
GTHX G1 Therapeutics	$7.15	$7.13	$1.08 ▼ $7.19	$373.81M	1.66	1.70 million shs	N/A
NKTR Nektar Therapeutics	$0.71 +21.4%	$0.71	$0.43 ▼ $1.93	$133.03M	0.62	1.83 million shs	3.61 million shs
YMAB Y-mAbs Therapeutics	$4.07 +4.6%	$4.55	$3.76 ▼ $16.11	$184.28M	0.53	316,178 shs	142,828 shs

Free Today: Your Guide to Smarter Options Trades

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANIX Anixa Biosciences	+1.92%	-5.34%	+3.10%	-14.19%	-11.33%
GTHX G1 Therapeutics	0.00%	0.00%	0.00%	0.00%	+49.90%
NKTR Nektar Therapeutics	+21.42%	+4.02%	+15.72%	+7.78%	-59.39%
YMAB Y-mAbs Therapeutics	+4.63%	-4.24%	-15.73%	-29.46%	-66.86%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ANIX Anixa Biosciences	2.0378 of 5 stars	3.6	3.0	0.0	1.6	1.7	0.0
GTHX G1 Therapeutics	0.366 of 5 stars	1.0	0.0	3.8	0.0	0.0	0.6
NKTR Nektar Therapeutics	3.9875 of 5 stars	3.5	3.0	4.2	2.1	2.5	0.0
YMAB Y-mAbs Therapeutics	3.8893 of 5 stars	4.4	3.0	0.0	2.6	4.2	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ANIX Anixa Biosciences	3.25	Buy	$9.00	238.35% Upside
GTHX G1 Therapeutics	2.00	Hold	$4.00	-44.06% Downside
NKTR Nektar Therapeutics	3.00	Buy	$4.50	529.55% Upside
YMAB Y-mAbs Therapeutics	2.82	Moderate Buy	$17.40	327.52% Upside

Current Analyst Ratings Breakdown

Latest ANIX, YMAB, GTHX, and NKTR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/12/2025	NKTR Nektar Therapeutics	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform
4/22/2025	YMAB Y-mAbs Therapeutics	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Neutral ➝ Underperform	$3.00
4/11/2025	NKTR Nektar Therapeutics	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Buy	$1.00 ➝ $2.00
4/10/2025	ANIX Anixa Biosciences	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00 ➝ $10.00
3/26/2025	ANIX Anixa Biosciences	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00 ➝ $10.00
3/25/2025	ANIX Anixa Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$7.00 ➝ $7.00
3/21/2025	ANIX Anixa Biosciences	Maxim Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$10.00
3/21/2025	YMAB Y-mAbs Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$22.00 ➝ $12.00
3/14/2025	NKTR Nektar Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Market Perform ➝ Outperform	$6.00
3/13/2025	NKTR Nektar Therapeutics	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform
3/13/2025	NKTR Nektar Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$6.50 ➝ $6.50

(Data available from 5/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ANIX Anixa Biosciences	$210K	407.83	N/A	N/A	$0.59 per share	4.51
GTHX G1 Therapeutics	$58.20M	6.42	N/A	N/A	$0.68 per share	10.51
NKTR Nektar Therapeutics	$98.43M	1.35	N/A	N/A	$0.69 per share	1.04
YMAB Y-mAbs Therapeutics	$87.69M	2.10	N/A	N/A	$2.32 per share	1.75

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ANIX Anixa Biosciences	-$12.55M	-$0.39	N/A	∞	N/A	N/A	-58.55%	-53.29%	6/3/2025 (Estimated)
GTHX G1 Therapeutics	-$47.97M	-$0.62	N/A	N/A	N/A	-76.93%	-136.98%	-39.33%	N/A
NKTR Nektar Therapeutics	-$276.06M	-$0.64	N/A	N/A	N/A	-180.70%	-173.28%	-46.31%	N/A
YMAB Y-mAbs Therapeutics	-$21.43M	-$0.67	N/A	N/A	N/A	-28.22%	-24.61%	-18.49%	5/13/2025 (Estimated)

Latest ANIX, YMAB, GTHX, and NKTR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
6/3/2025	Q2 2025	ANIX Anixa Biosciences	-$0.10	N/A	N/A	N/A	N/A	N/A
5/13/2025	Q1 2025	YMAB Y-mAbs Therapeutics	-$0.21	-$0.12	+$0.09	-$0.12	$19.97 million	N/A
5/8/2025	Q1 2025	NKTR Nektar Therapeutics	-$0.18	-$0.22	-$0.04	-$0.24	$15.61 million	$10.46 million
3/12/2025	Q4 2024	NKTR Nektar Therapeutics	-$0.18	$0.15	+$0.33	$0.03	$36.65 million	$29.18 million
3/11/2025	Q1 2025	ANIX Anixa Biosciences	-$0.10	-$0.10	N/A	-$0.10	N/A	N/A
3/4/2025	Q4 2024	YMAB Y-mAbs Therapeutics	-$0.13	-$0.15	-$0.02	-$0.15	$26.70 million	$26.50 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ANIX Anixa Biosciences	N/A	N/A	N/A	N/A	N/A
GTHX G1 Therapeutics	N/A	N/A	N/A	N/A	N/A
NKTR Nektar Therapeutics	N/A	N/A	N/A	N/A	N/A
YMAB Y-mAbs Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ANIX Anixa Biosciences	N/A	8.54	8.54
GTHX G1 Therapeutics	1.34	2.48	2.12
NKTR Nektar Therapeutics	N/A	4.24	4.24
YMAB Y-mAbs Therapeutics	N/A	3.92	3.54

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ANIX Anixa Biosciences	29.13%
GTHX G1 Therapeutics	24.21%
NKTR Nektar Therapeutics	75.88%
YMAB Y-mAbs Therapeutics	70.85%

Insider Ownership

Company	Insider Ownership
ANIX Anixa Biosciences	25.30%
GTHX G1 Therapeutics	6.11%
NKTR Nektar Therapeutics	5.25%
YMAB Y-mAbs Therapeutics	22.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ANIX Anixa Biosciences	5	32.20 million	24.05 million	Optionable
GTHX G1 Therapeutics	170	52.28 million	49.09 million	Optionable
NKTR Nektar Therapeutics	220	186.10 million	177.62 million	Optionable
YMAB Y-mAbs Therapeutics	150	45.28 million	34.71 million	Optionable

ANIX, YMAB, GTHX, and NKTR Headlines

Recent News About These Companies

Y-mAbs to Host Virtual Radiopharmaceutical R&D Update on May 28, 2025

May 13 at 7:05 AM | globenewswire.com

Y-mAbs Reports First Quarter 2025 Financial Results and Recent Corporate Developments

May 13 at 6:35 AM | globenewswire.com

Y-mAbs Announces Update to National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for Neuroblastoma to Include Naxitamab-gqgk (DANYELZA®)

May 7, 2025 | globenewswire.com

Why Y-mAbs Therapeutics, Inc.’s (YMAB) Stock Is Down 5.65%

May 6, 2025 | aaii.com

Y-mAbs to Announce First Quarter 2025 Financial and Operating Results on May 13, 2025

May 6, 2025 | globenewswire.com

Short Interest in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Drops By 16.1%

May 5, 2025 | marketbeat.com

2,861,825 Shares in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Acquired by Acorn Capital Advisors LLC

May 4, 2025 | marketbeat.com

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Short Interest Down 16.1% in April

May 4, 2025 | americanbankingnews.com

Caligan Partners LP Has $13.84 Million Stock Position in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)

May 3, 2025 | marketbeat.com

Renaissance Technologies LLC Raises Position in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)

May 3, 2025 | marketbeat.com

Y-mAbs Therapeutics (YMAB) Projected to Post Earnings on Tuesday

May 1, 2025 | marketbeat.com

JPMorgan Chase & Co. Raises Stock Holdings in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)

April 30, 2025 | marketbeat.com

Earnings Preview: Y-mAbs Therapeutics, Inc. (YMAB) Q1 Earnings Expected to Decline

April 29, 2025 | zacks.com

Boothbay Fund Management LLC Buys 136,264 Shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)

April 29, 2025 | marketbeat.com

Y-mAbs Therapeutics announces presentation of PK data of CD38-SADA

April 28, 2025 | markets.businessinsider.com

Y-mAbs Therapeutics, Inc.'s (NASDAQ:YMAB) latest 13% decline adds to one-year losses, institutional investors may consider drastic measures

April 27, 2025 | finance.yahoo.com

Y-mAbs Presents Translational Pharmacokinetics of CD38-SADA from Pretargeted RIT Platform at 2025 American Association for Cancer Research (AACR) Annual Meeting

April 27, 2025 | globenewswire.com

Brookline Capital Management Weighs in on YMAB Q1 Earnings

April 27, 2025 | marketbeat.com

Y-mAbs announces first patient dosed in Phase 1 trial of CD38-SADA PRIT platform

April 26, 2025 | markets.businessinsider.com

Y-mAbs Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating CD38-SADA Pre-targeted Radioimmunotherapy in Relapsed/Refractory Non-Hodgkin Lymphoma

April 25, 2025 | globenewswire.com

Y-mAbs Therapeutics (NASDAQ:YMAB) Downgraded to "Underperform" Rating by Bank of America

April 24, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANIX, YMAB, GTHX, and NKTR Company Descriptions

Anixa Biosciences NASDAQ:ANIX

$2.66 +0.05 (+1.92%)

Closing price 05/12/2025 03:58 PM Eastern

Extended Trading

$2.78 +0.12 (+4.51%)

As of 08:00 AM Eastern

Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a preventative vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.

G1 Therapeutics NASDAQ:GTHX

G1 Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer in the United States. The company offers COSELA, which helps to decrease incidence of chemotherapy-induced myelosuppression in adult patients treated with a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer. It is also developing Trilaciclib that is in Phase 3 clinical trial for 1L metastatic triple negative breast cancer (mTNBC); and Phase 2 clinical trial as an antibody-drug conjugate combination trial in mTNBC, as well as completed Phase 2 clinical trial for Neoadjuvant TNBC and 1L Bladder cancer. The company has a license agreement with Genor Biopharma Co. Inc. for the development and commercialization of lerociclib using an oral dosage form to treat various indication in humans; Incyclix for the development and commercialization of a CDK2 inhibitor for all human and veterinary uses; and Simcere Pharmaceutical Co., Ltd for the development and commercialization of trilaciclib in all indications. G1 Therapeutics, Inc. was incorporated in 2008 and is headquartered in Research Triangle Park, North Carolina.

Nektar Therapeutics NASDAQ:NKTR

$0.71 +0.13 (+21.42%)

Closing price 05/12/2025 04:00 PM Eastern

Extended Trading

$0.74 +0.03 (+3.53%)

As of 08:00 AM Eastern

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California.

Y-mAbs Therapeutics NASDAQ:YMAB

$4.07 +0.18 (+4.63%)

Closing price 05/12/2025 04:00 PM Eastern

Extended Trading

$4.06 -0.02 (-0.37%)

As of 08:00 AM Eastern

Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow. The company is also developing DANYELZA for the treatment of patients with second-line relapsed osteosarcoma and is in Phase II clinical study; GD2-SADA, which is in Phase I clinical trial for the treatment of GD2 positive solid tumor; and Omburtamab, a murine monoclonal antibody for the treatment of central nervous system/leptomeningeal metastases from neuroblastoma, as well as SADA PRIT technology platform. In addition, it is engages in the developing of CD38-SADA and GD2-GD3 Vaccine. The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products. Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time